The BioMedBC Project is focused on improving our understanding of BC at the molecular level and in deciphering molecular key
elements implicated in disease outcome to further introduce prognostic biomarkers. The expected outcome will form the basis for
patient stratification in order to assist appropriate treatment selection towards BC personalized medicine.
BioMedBC Project aims to establish molecular profiles which predict drug response and clinical outcome to improve on BC
management,through the following objectives (Figure 1):
- Molecular characterization of BC, through cross-omics correlation of tissue and urinary proteomics datasets combined with publicly available transcriptomics data.
- Delivery of predictive algorithms/BM, associated with disease outcome (prognostic value).
- Integration of data via bioinformatics tools to reveal molecular pathways and drug targets or predict resistance to therapeutic schemes.
Three main sources will be utilised for data retrieval:
a) experimental, tissue and urinary proteomics datasets
b) large well characterised prospective cohorts from BC patients and their urinary profiling datasets,
c) publicly available transcriptomics datasets, retrieved from previously published studies (e.g. TCGA Project).
The concept of the BioMedBC Proposal is to integrate these available clinical, demographical and -omics datasets,
in order to fully explore the molecular profiles in relation to the clinical outcome.
BioMedBC is a Marie Sklodowska Curie Actions (MSCA) Individual Fellowship programme (H2020-MSCA-IF-2016)
funded by the European Union under the Horizon2020 Framework Programme (Grant Agreement:752755) and
coordinated by Mosaiques diagnostics